Epigenetics of methylation modifications in diabetic cardiomyopathy

Front Endocrinol (Lausanne). 2023 Mar 15:14:1119765. doi: 10.3389/fendo.2023.1119765. eCollection 2023.

Abstract

Type 2 diabetes is one of the most common metabolic diseases with complications including diabetic cardiomyopathy and atherosclerotic cardiovascular disease. Recently, a growing body of research has revealed that the complex interplay between epigenetic changes and the environmental factors may significantly contribute to the pathogenesis of cardiovascular complications secondary to diabetes. Methylation modifications, including DNA methylation and histone methylation among others, are important in developing diabetic cardiomyopathy. Here we summarized the literatures of studies focusing on the role of DNA methylation, and histone modifications in microvascular complications of diabetes and discussed the mechanism underlying these disorders, to provide the guidance for future research toward an integrated pathophysiology and novel therapeutic strategies to treat or prevent this frequent pathological condition.

Keywords: DNA methyaltion; T2DM; diabetic cardiomyopathy; epigenetic; histone methylation.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA Methylation
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / genetics
  • Diabetic Cardiomyopathies* / genetics
  • Epigenesis, Genetic
  • Humans
  • Protein Processing, Post-Translational

Grants and funding

This research was supported by the Tian-Qing Hospital Medical Project of the Jiangsu Pharmaceutical Association (2020) and the Specially Appointed Medical Expert Project of the Jiangsu Commission of Health (2019).